Abstract:Abstract Background Atherosclerosis is a chronic lipid-driven inflammatory disease with infiltration of low-density lipoprotein and is considered as the pivotal step in plaque formation. The aim of the review is to get into the fine details of pathophysiologic mechanisms responsible for atherosclerosis with atherosclerotic lesion classification. It also provides a summary of current biomarkers other than the traditional risk factors so that new treatment modalities can emerge and reduce the morbidity and mortality associated with atherosclerosis. Main body In the classification of atherosclerosis made by American Heart Association (AHA), AHA Type I lesion is the earliest vascular change described microscopically. AHA Type II lesion is primarily composed of abundant macrophages. AHA Type III lesion is the earliest of progressive lesions, while AHA Type IV lesion consists of an acellular necrotic core. Various biomarkers are implicated in different stages of the pathophysiological mechanism of plaque formation and evolution. C Reactive Protein plays a direct role in promoting the inflammatory component of atherosclerosis. Fibrinogen was demonstrated to be elevated among patients with acute thrombosis. Higher leukocyte count is associated with a greater cardiovascular risk. Cytokines have been implicated in atheroma formation and complications. High rates of protease activated receptor expression are also induced by interleukin-6 secretion in atherosclerotic lesions and areas of vascular tissue injury. Cluster of differentiation 40 receptor and its ligand have been also detected in atherosclerotic plaques. Osteopontin, acidic phosphoprotein, and osteoprotegerin have emerged as novel markers of atherosclerotic plaque composition. There are also overproductions of matrix metalloproteinases in the rupture-prone regions and promote lipid-necrotic core formation in the atherosclerotic plaque. Myeloperoxidase has been proposed as a marker of plaque instability. Oxidized low-density lipoprotein receptor 1 provides a route of entry for oxidized low-density lipoprotein into the endothelium. A human atherosclerotic lesion also expresses lipoprotein-associated phospholipase A 2 . Short conclusion Atherosclerotic plaques are the battlefield between an unbalanced immune response and lipid accumulation in the intima of arteries. Most of the biomarkers associated with atherosclerosis are indicators of inflammatory response and will also be used for medical purposes.

Discerning the promising binding sites of S100/calgranulins and their therapeutic potential in atherosclerosis

Nanocarrier-Based Targeting of Cluster of Differentiation 44 for Treating Atherosclerosis: A Review

Receptor for Advanced Glycation End Products Involved in Circulating Endothelial Cells Release from Human Coronary Endothelial Cells Induced by C-reactive Protein

Cytokines and atherosclerosis: a comprehensive review of studies in mice

Unraveling the Mechanisms of S100A8/A9 in Myocardial Injury and Dysfunction

Computational inhibition of S100A8 (calgranulin A) as a potential non-invasive biomarker for rheumatoid arthritis

S100a8/A9 proteins: critical regulators of inflammation in cardiovascular diseases

Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective

The cellular biology of atherosclerosis with atherosclerotic lesion classification and biomarkers

Advances in the study of S100A9 in cardiovascular diseases

Innate Immune Pathways in Atherosclerosis—From Signaling to Long-Term Epigenetic Reprogramming

Biomarkers of Atherosclerotic Plaque Vulnerability and Their Clinical Significance

A proteome-wide screen identifies the calcium binding proteins, S100A8/S100A9, as clinically relevant therapeutic targets in aortic dissection

S100A8/A9: From basic science to clinical application

Role of sirtuins in attenuating plaque vulnerability in atherosclerosis

Advanced Glycation End Products: key player of the pathogenesis of atherosclerosis

Targeting immune cell recruitment in atherosclerosis

Molecular chaperones and heat shock proteins in atherosclerosis

Computational Deciphering of the Role of S100A8 and S100A9 Proteins and Their Changes in the Structure Assembly Influences Their Interaction with TLR4, RAGE, and CD36

A New Therapeutic End for Atherosclerotic Cardiovascular Disease

Overview of multifunctional cysteinyl cathepsins in atherosclerosis-based cardiovascular disease: from insights into molecular functions to clinical implications